Three amino acids. That’s it. Lysine-Proline-Valine — a tripeptide so small it barely qualifies as a peptide at all. But KPV has generated outsized research interest because this tiny fragment, snipped from the tail end of alpha-MSH, packs anti-inflammatory activity that works through mechanisms most conventional anti-inflammatory compounds don’t touch.
Here’s what the published research shows about the smallest peptide doing some of the biggest work in inflammation research.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
Where KPV Comes From: The Alpha-MSH Connection
Alpha-melanocyte-stimulating hormone (α-MSH) is a 13-amino-acid peptide your body produces naturally. It’s best known for stimulating melanocytes (tanning), but it’s also a potent anti-inflammatory signal — it suppresses NF-κB activation, reduces pro-inflammatory cytokine production, and modulates immune cell behavior.
Researchers studying α-MSH wanted to know: which part of the molecule is responsible for the anti-inflammatory effects? Through systematic fragmentation studies, they identified KPV — the last three amino acids at the C-terminal end (positions 11-13) — as carrying much of the anti-inflammatory activity. Remarkably, this tripeptide retained significant biological activity even though it’s too small to bind melanocortin receptors in the traditional way.
How Does Something This Small Work?
This is the interesting part. Most peptide drugs work by binding to a receptor on the cell surface. KPV appears to bypass that entirely. Published research suggests it works through:
Direct NF-κB Inhibition
NF-κB is the master switch for inflammatory gene expression. When activated, it turns on the production of cytokines (IL-1β, IL-6, TNF-α), chemokines, adhesion molecules — the whole inflammatory cascade. KPV enters cells and inhibits NF-κB nuclear translocation, effectively keeping the switch in the “off” position. No receptor required — the peptide gets inside the cell and acts directly on the signaling machinery.
Inflammasome Suppression
Research has also shown KPV inhibiting NLRP3 inflammasome activation — the protein complex responsible for processing and releasing IL-1β and IL-18, two cytokines central to chronic inflammatory conditions. This adds a second layer of anti-inflammatory mechanism beyond NF-κB inhibition.
Cell Penetration
KPV’s small size actually works in its favor for cell entry. It can cross cell membranes more readily than larger peptides, which is likely why it can act on intracellular targets like NF-κB. Some researchers have explored PepT1 transporter-mediated uptake in intestinal epithelial cells as a specific entry mechanism — particularly relevant for gut inflammation applications.
The Research Highlights
Gut Inflammation
This is KPV’s strongest research area. Dalmasso et al. published studies showing that KPV reduced inflammation in colitis models — both in cell culture (Caco-2 intestinal cells) and in vivo (DSS-induced and TNBS-induced colitis in mice). Treated animals showed reduced disease activity scores, less mucosal damage, and lower inflammatory cytokine levels. The PepT1 transporter finding is especially relevant here — it provides a specific uptake mechanism in exactly the tissue where the inflammation occurs.
Skin Inflammation
Given α-MSH’s natural role in skin biology, KPV has been studied in dermatological inflammation models. Research has shown reduced inflammatory markers and improved outcomes in models of contact dermatitis and other skin inflammatory conditions. The peptide’s small size makes it potentially compatible with topical delivery — crossing the skin barrier is easier when you’re only three amino acids.
Antimicrobial Properties
An unexpected finding: KPV demonstrated antimicrobial activity against certain bacterial species, including Staphylococcus aureus and Candida albicans. The mechanism appears to involve disruption of microbial membrane integrity — adding another dimension to its potential in infection-associated inflammation.
Why Size Matters (In This Case, Small Is Better)
KPV’s tiny size gives it several practical advantages over larger anti-inflammatory peptides:
- Cheap to synthesize — three residues means low production cost and high yield
- Stable — fewer bonds to break, less susceptible to many degradation pathways
- Cell-permeable — can reach intracellular targets that larger molecules can’t
- Multiple delivery routes — small enough for potential oral, topical, and injectable applications
- Low immunogenicity — too small to trigger significant immune responses
Product Specifications
- Sequence: Lys-Pro-Val (KPV)
- Molecular Weight: 342.43 g/mol
- CAS Number: 67727-97-3
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Freely soluble in bacteriostatic water
Key References
- Brzoska T, et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects. Endocr Rev. 2008;29(5):581-602.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflamm Bowel Dis. 2008;14(3):324-331.
Browse KPV 10mg with verified COA from Janoshik Analytical. For related anti-inflammatory research, explore BPC-157 and GHK-Cu.